AstraZeneca PLC says a U.S. court has dismissed the company's bid to extend the patent on Seroquel, its blockbuster drug for the treatment of bipolar disorder.
AstraZeneca said Monday that the suit against the U.S. Food and Drug Administration had been dismissed on Friday in Washington D.C.
The pharmaceutical company was seeking to extend its patents on quetiapine, the active ingredient in the medication, and on the formula for Seroquel XR, the extended-release version.
Astra Zeneca was seeking to protect its patents from generic competitors in the United States until December. The company says it is evaluating its legal options.